FDA
FDA approves interchangeable insulin glargine biosimilar Langlara
Image source: Business Wire
Basal insulin affordability remains a persistent barrier in diabetes management, even as biosimilars expand treatment options. However, not all insulin biosimilars function the same way at the point of dispensing.
The FDA has approved Langlara (insulin glargine‑aldy) as an interchangeable biosimilar to Lantus for adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Interchangeability is significant because it confers legal authority—subject to state law—for pharmacists to substitute Langlara for a prescribed Lantus product without contacting the prescriber.
This distinction matters clinically. While multiple insulin glargine biosimilars are available, only those granted interchangeability can be automatically substituted at the pharmacy, positioning pharmacists as direct facilitators of access to potentially lower‑cost therapy at the moment of dispensing.
Recent FDA policy changes may further amplify this impact. In June 2024, the agency updated its draft guidance, eliminating the prior requirement for repeated clinical switching studies. Manufacturers may now demonstrate interchangeability based on existing analytical and clinical evidence, a change associated with faster approvals.
Langlara’s approval was supported by a comprehensive analytical, preclinical, and clinical program showing comparable pharmacokinetics/pharmacodynamics, efficacy, safety, and immunogenicity to Lantus. The drug manufacturer has indicated plans to pursue broad formulary placement.
For clinicians, interchangeable insulins like Langlara may offer greater prescribing flexibility while supporting continuity of care when pharmacy substitution occurs.
“Often, the greatest barrier to care for patients living with diabetes is the cost or the availability of the medicine itself," said Tim Crew, CEO of Lannett. "Upon the launch of Langlara...patients will have expanded access to a safe, affordable and available treatment option.”
Source: Lannett Company, Inc. (2026, May 4). Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus (insulin glargine)